| ASCO 2022 MRx0518 and Bavencio Trial In Progress | RNS | 27.05.22 | 07:00:02 |
| Annual Report and Notice of AGM | RNS | 25.05.22 | 13:51:42 |
| ATS 2022 - MRx-4DP0004 Phase I/II Part A poster | RNS | 17.05.22 | 07:00:09 |
| Final Results | RNS | 01.04.22 | 07:00:09 |
| Holding(s) in Company | RNS | 24.03.22 | 10:50:09 |
| MRx0518 + Keytruda - Primary endpoint met in RCC | RNS | 23.03.22 | 07:00:05 |
| Holding(s) in Company | RNS | 21.03.22 | 10:46:41 |
| Form F3 Registration Statement filed with SEC | RNS | 09.03.22 | 07:00:10 |
Holding(s) in Company 24 February 2022 07:21:05 | RNS | 24.02.22 | 07:21:05 |
Participation in Chardan Microbiome Summit 23 February 2022 07:00:05 | Reach | 23.02.22 | 07:00:05 |
Parkinson’s trial receives FDA IND clearance 22 February 2022 07:00:07 | RNS | 22.02.22 | 07:00:07 |
Restatement of Interim Results to June 30, 2021 18 February 2022 07:00:09 | RNS | 18.02.22 | 07:00:09 |
| Additional MRx04 Phase 1/2 asthma data and event | RNS | 27.01.22 | 07:00:09 |
| Holding(s) in Company | RNS | 25.01.22 | 17:17:07 |
| 4D pharma to host virtual KOL event | RNS | 20.01.22 | 07:00:09 |
| Holding(s) in Company | RNS | 06.01.22 | 10:07:35 |
| Participation in Upcoming Investor Conference | Reach | 05.01.22 | 07:00:08 |
| Grant of Options | RNS | 04.01.22 | 07:00:13 |
| 4D pharma appoints John Doyle as CFO | RNS | 04.01.22 | 07:00:13 |
4D pharma Phase 1/2 asthma study Part A results 13 December 2021 07:00:08 | RNS | 13.12.21 | 07:00:08 |
